Kangmei Pharmaceutical Co., Ltd.

600518

CNE0000017M1

Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products intended primarily for treating hypertension and colds. The group offers Chinese medications (ginseng, salvia, codonopsis, etc.) and chemical medications (clarithromycin, doxazosin mesylate, paracetamol, etc.). All sales are earned in China.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KANGMEI PHARMACEUTICAL CO., LTD.	+3.76%	3.69B
NOVO NORDISK A/S	+25.07%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.42%	233B
NOVARTIS AG	+5.62%	201B
ROCHE HOLDING AG	-10.10%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.93 ^CNY	+1.05%		+0.52%	+3.76%

Apr. 15	Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%	MT
Apr. 12	Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%	Apr. 14	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit	Mar. 26	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019	22-07-19	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence	22-01-11	MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.	21-12-14	CI
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.	21-12-13	CI
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms	21-11-21	MT
Kangmei to Get $1 Billion Government-Led Bailout	21-11-02	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-27	CI
Kangmei Pharmaceutical Co., Ltd. Appoints Zhou Yunfeng as Secretary to Directorate	21-02-18	CI
Market Chatter: GF Securities to Rejig Banking Operations After Client's Nearly $13 Billion Fraud Scandal	20-11-11	MT
Kangmei Pharmaceutical : Prices of China's Traditional Medicinal Materials Rise Tuesday	20-11-03	MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI
Kangmei Pharmaceutical Co., Ltd. Approves Appointment of Gong Guibo as Deputy General Manager	20-10-11	CI

Kangmei Pharmaceutical Co., Ltd.

Equities

600518

CNE0000017M1

Pharmaceuticals

Latest news about Kangmei Pharmaceutical Co., Ltd.

Chart Kangmei Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals